Dr. Samantha Correia
Group Leader, Vector Technologies
Samantha brings over a decade of experience in molecular biology, specialising in DNA design and optimisation, including five years of gene therapy research in industry. At ExEd, she plays a central role in advancing our understanding of how transgene & vector design influences protein production, translating this expertise into collaborative projects both internally and with commercial partners.
Bio
Samantha completed her BSc at the University of Leeds specialising in Virology. She continued with a MRes & PhD at Imperial University continuing her focus on virology, with a PhD focused on Epstein Barr virus genetics under the supervision of Prof Paul Farrell.
Prior to joining ExEd’s, Samantha has spent 5 years within the gene therapy field focusing on AAV cassette & vector optimisation. She has worked on optimising AAV delivering liver-directed proteins & CNS-directed miRNAs. She has extensive knowledge on promoter design, transgene optimisation & AAV biology to improve therapeutic candidates & has been able to improve AAV mediated protein expression by 100-fold through AAV cassette modifications.
Prior to joining ExEd, Samantha held Senior Scientist roles in the gene therapy biotechs Freeline Therapeutics and AviadoBio.
Samantha brings over a decade of experience in molecular biology, specialising in DNA design and optimisation, including five years of gene therapy research in industry. At ExEd, she plays a central role in advancing our understanding of how transgene & vector design influences protein production, translating this expertise into collaborative projects both internally and with commercial partners.
Bio
Samantha completed her BSc at the University of Leeds specialising in Virology. She continued with a MRes & PhD at Imperial University continuing her focus on virology, with a PhD focused on Epstein Barr virus genetics under the supervision of Prof Paul Farrell.
Prior to joining ExEd’s, Samantha has spent 5 years within the gene therapy field focusing on AAV cassette & vector optimisation. She has worked on optimising AAV delivering liver-directed proteins & CNS-directed miRNAs. She has extensive knowledge on promoter design, transgene optimisation & AAV biology to improve therapeutic candidates & has been able to improve AAV mediated protein expression by 100-fold through AAV cassette modifications.
Prior to joining ExEd, Samantha held Senior Scientist roles in the gene therapy biotechs Freeline Therapeutics and AviadoBio.
Samantha brings over a decade of experience in molecular biology, specialising in DNA design and optimisation, including five years of gene therapy research in industry. At ExEd, she plays a central role in advancing our understanding of how transgene & vector design influences protein production, translating this expertise into collaborative projects both internally and with commercial partners.
Bio
Samantha completed her BSc at the University of Leeds specialising in Virology. She continued with a MRes & PhD at Imperial University continuing her focus on virology, with a PhD focused on Epstein Barr virus genetics under the supervision of Prof Paul Farrell.
Prior to joining ExEd’s, Samantha has spent 5 years within the gene therapy field focusing on AAV cassette & vector optimisation. She has worked on optimising AAV delivering liver-directed proteins & CNS-directed miRNAs. She has extensive knowledge on promoter design, transgene optimisation & AAV biology to improve therapeutic candidates & has been able to improve AAV mediated protein expression by 100-fold through AAV cassette modifications.
Prior to joining ExEd, Samantha held Senior Scientist roles in the gene therapy biotechs Freeline Therapeutics and AviadoBio.
→